Product category:
Antibodies
News Release from: BAC Bio Affinity Company | Subject: CaptureSelect ligands
Edited by the Laboratorytalk Editorial
Team on 04 May 2007
Vaccine purification deal with Sanofi
Pasteur
BAC's CaptureSelect customised affinity ligands have been selected by Sanofi Pasteur as they potentially offer high stability and specificity for process-scale purification of some vaccine products
BAC has entered into an agreement with Sanofi Pasteur, the vaccines business of Sanofi-Aventis Sanofi Pasteur is one of the world's largest companies dedicated to developing human vaccines
This article was originally published on Laboratorytalk on 14 Nov 2007 at 8.00am (UK)
Related stories
Remove the uncertainty in selecting affinity media
Antibody Toolbox offers researchers a range of products that will simplify and streamline purification protocols, eliminating many drawbacks of the current gold-standards for antibody purification
Leukaemia classification gets tighter in Leeds
The Haematological Malignancy Diagnostic Service based at Leeds General Infirmary has made significant improvements to its leukaemia diagnosis and classification service
Reagents speed up leukaemia diagnosis
"The reagents that are used to diagnose haematological malignancies have undergone vast improvements in the last couple of years"
Manufactured using a high-yielding proprietary yeast-based expression system, which is completely animal-free, CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and offer enhanced stability and broad antigen-specific binding compared to traditional affinity media.
BAC says it has built a strong reputation for rapid discovery and development of customised ligands for chromatographic separation of a wide range of biological materials including monoclonal antibodies, antibody fragments, recombinant proteins and micro organisms for biopharmaceutical manufacture.
"This is a significant collaboration for BAC and we are proud to have been selected by Sanofi Pasteur for this exciting project," said Laurens Sierkstra, CEO of BAC.
"This latest agreement further endorses the suitability of our CaptureSelect technology for commercial-scale bioprocessing".
BAC - the bio affinity company - offers a wide range of products and services for affinity purification of biological materials from complex media.
The company's proprietary CaptureSelect affinity ligands, based on Camelid single chain antibody fragments, have been proven to be suitable in a wide range of biological applications including life science research, biomanufacturing and healthcare.
CaptureSelect ligand technology is based on selection of single chain antibody fragments with desirable chromatographic characteristics including robustness, high specificity and flexibility.
Suitable ligands are cloned and expressed in high-titers through an animal-free Saccharomyces cerevisiae-based process.
BAC was established in 1995 as a Unilever subsidiary.
Currently the company employs 28 people with an R+D laboratory facility in Vlaardingen and a state-of-the-art ISO 9001 certified manufacturing plant in Naarden, Netherlands.
• BAC Bio Affinity Company: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
